Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
- 22 September 2017
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 17 (11) , 88
Abstract
This paper will systemically review the risk of infections associated with current disease-modifying treatments and will discuss pre-treatment testing recommendations, infection monitoring strategies, and patient education. Aside from glatiramer acetate and interferon-beta therapies, all other multiple sclerosis treatments to various degrees impair immune surveillance and may predispose patients to the development of both community-acquired and opportunistic infections. Some of these infections are rarely seen in neurologic practice, and neurologists should be aware of how to monitor for these infections and how to educate patients about medication-specific risks. Of particular interest in this discussion is the risk of PML in association with the recently approved B cell depleting therapy, ocrelizumab, particularly when switching from natalizumab. The risk of infection in association with MS treatments has become one of the most important factors in the choice of therapy. Balance of the overall risk versus benefit should be continuously re-evaluated during treatment.Keywords
This publication has 81 references indexed in Scilit:
- Effects of dimethyl fumarate on neuroprotection and immunomodulationJournal of Neuroinflammation, 2012
- Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 PathwayThe Journal of Pharmacology and Experimental Therapeutics, 2012
- IFN-β induces the proliferation of CD4+CD25+Foxp3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosisJournal of Neuroimmunology, 2011
- Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid ArthritisArchives of Neurology, 2011
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences, 2007
- Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell levelImmunology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple SclerosisDrug Safety, 2004